Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study examined the effect of
hepatoma
-associated antigen HAb18G (homologous to
CD147
) expression on the NO/cGMP-regulated Ca(2+) mobilization and metastatic process of human
hepatoma
cells. HAb18G/
CD147
cDNA was transfected into human 7721
hepatoma
cells to obtain a cell line stably expressing HAb18G/
CD147
, T7721, as demonstrated by Northern blot and immunocytochemical studies. 8-Bromo-cGMP (cGMP) inhibited the thapsigargin-induced Ca(2+) entry in a concentration-dependent manner in 7721 cells. The cGMP-induced inhibition was abolished by an inhibitor of protein kinase G, KT5823 (1 microm). However, expression of HAb18G/
CD147
in T7721 cells decreased the inhibitory response to cGMP. A similar concentration-dependent inhibitory effect on the Ca(2+) entry was observed in 7721 cells in response to a NO donor, (+/-)-S-nitroso-N-acetylpenicillamine (SNAP). The inhibitory effect of SNAP on the thapsigargin-induced Ca(2+) entry was significantly reduced in HAb18G/
CD147
-expressing T7721 cells, indicating a role for HAb18G/
CD147
in NO/cGMP-regulated Ca(2+) entry. Experiments investigating metastatic potentials demonstrated that HAb18G/
CD147
-expressing T7721 cells attached to the Matrigel-coated culture plates and invaded through Matrigel-coated permeable filters at the rate significantly greater than that observed in 7721 cells. Both the attachment and invasion rates could be suppressed by SNAP, and the inhibitory effect of SNAP could be reversed by NO inhibitor, N(G)-nitro-l-arginine methyl ester. The sensitivity of the attachment and invasion rates to cGMP was significantly reduced in T7721 cells as compared with 7721 cells when cells were pretreated with thapsigargin. The difference in the sensitivity between the two cells could be abolished by a Ca(2+) channel blocker, Ni(2+) (3 mm). These results suggest that HAb18G/
CD147
enhances metastatic potentials in human
hepatoma
cells by disrupting the regulation of store-operated Ca(2+) entry by NO/cGMP.
...
PMID:The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. 1159 20
HAb18G/
CD147
is a heavily glycosylated protein containing two immunoglobulin superfamily domains. Our previous studies have indicated that overexpression of HAb18G/
CD147
enhances metastatic potentials in human
hepatoma
cells by disrupting the regulation of store-operated Ca2+ entry by nitric oxide (NO)/cGMP. In the present study, we investigated the structure-function of HAb18G/
CD147
by transfecting truncated HAb18G/
CD147
fragments into human 7721
hepatoma
cells. The inhibitory effect of HAb18G/
CD147
on 8-bromo-cGMP-regulated thapsigargin-induced Ca2+ entry was reversed by the expression of either C or N terminus truncated HAb18G/
CD147
in T7721deltaC and T7721deltaN cells, respectively. The potential effect of HAb18G/
CD147
on metastatic potentials, both adhesion and invasion capacities, of
hepatoma
cells was abolished in T7721deltaC cells, but not affected in T7721deltaN cells. Release and activation of matrix metalloproteinases (MMPs), MMP-2 and MMP-9, were found to be enhanced by the expression of HAb18G/
CD147
, and this effect was abolished by both truncations. Thapsigargin significantly enhanced release and activation of MMPs (MMP-2 and MMP-9) in non-transfected 7721 cells, and this effect was negatively regulated by SNAP. However, no effects of thapsigargin or SNAP were observed in T7721 cells, and expression of HAb18G/
CD147
enhanced secretion and activation of MMPs at a stable and high level. Taken together, these results suggest that both ectodomain and intracellular domains of HAb18G/
CD147
are required to mediate the effect of HAb18G/
CD147
on the secretion and activation of MMPs and metastasis-related processes in human
hepatoma
cells by disrupting the regulation of NO/cGMP-sensitive intracellular Ca2+ mobilization although each domain may play different roles.
...
PMID:HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. 1531 57
The present study examined the effect of
hepatoma
-associated antigen HAb18G (homologous to
CD147
) expression on the NO/cGMP-regulated Ca2+ mobilization to induce matrix metalloproteinases (MMP) production and attenuate adhesion ability of mouse fibroblast NIH/3T3 cells. HAb18G/
CD147
cDNA was transfected into fibroblast 3T3 cells to obtain a cell line stably expressing HAb18G/
CD147
, t3T3, as demonstrated by immunofluorescence staining and flow cytometry assays. 8-Bromo-cGMP inhibited the thapsigargin-induced Ca2+ entry in 3T3 cells, whereas an inhibitor of protein kinase G, KT5823 (1 microM), led to an increase in Ca2+ entry. Expression of HAb18G/
CD147
in t3T3 cells decreased the inhibitory response to cGMP. A similar effect on the Ca2+ entry was observed in 3T3 cells in response to an NO donor, (+/-)-S-nitroso-N-acetylpenicillamine (SNAP). The inhibitory effect of SNAP on the thapsigargin-induced Ca2+ entry was also reduced in HAb18G/
CD147
-expressing t3T3 cells, indicating a role for HAb18G/CD 147 in NO/cGMP-regulated Ca2+ entry. Results of gelatin zymography assays showed that addition of extracellular Ca2+ induced MMP (MMP-2, MMP-9) release and activation in a dose-dependent manner, and expression of HAb18G/
CD147
enhanced the secretion of MMP-2 and MMP-9 in 3T3 cells. 8-Bromo-cGMP and SNAP reduced the production of MMP in 3T3 cells but not in t3T3 with HAb18G/
CD147
expression. RT-PCR experiments substantiated that the expression of MMP-2 and MMP-9 mRNA in HAb18G/CD 147-expressing t3T3 cell was significantly greater than that in 3T3 cells. Experiments investigating adhesion potentials demonstrated that HAb18G/
CD147
-expressing t3T3 cells pretreated with Ca2+ attached to Matrigel-coated culture plates significantly less efficiently than 3T3 cells. The proportion of attached cells could be increased by treatment with 8-bromo-cGMP and SNAP in 3T3 cells, but not in t3T3. These results suggest that HAb18G/
CD147
attenuates adhesion potentials in fibroblasts by enhancing the secretion of MMP through NO/cGMP-sensitive capacitative Ca2+ entry.
...
PMID:HAb18G/CD147 enhances the secretion of matrix metalloproteinases (MMP) via cGMP/NO-sensitive capacitative calcium entry (CCE) and accordingly attenuates adhesion ability of fibroblasts. 1572 16
CD147
which is a regulator of matrix metalloproteinase (MMP) production on the surface of many malignant tumor cells, shows a highly specific association with caveolin-1 (Cav-1). As a result of heterogeneous N-glycosylation,
CD147
exists in both highly glycosylated form, HG-
CD147
( approximately 40-60kDa) and lowly glycosylated form, LG-
CD147
( approximately 32kDa). This study investigated the possible role of Cav-1 in
CD147
glycosylation in the HcaF, HcaP and Hepa1-6 mouse
hepatocarcinoma
cell lines, which have high, low and no metastatic potential in the lymph nodes, respectively, and in the normal mouse liver cell line IAR-20. Using an RNA interference (RNAi) strategy, we showed that the down-regulation of Cav-1 in Hca-F/RNAi cells could suppress the conversion of LG-
CD147
to HG-
CD147
, down-regulate MMP-11 expression and decrease Hca-F/RNAi cell invasion. Conversely, a stable high expression of Cav-1 in Hepa1-6/Cav-1 cell could cause a specific increase of HG-
CD147
, up-regulate MMP-11 protein expression and enhance Hepa1-6/Cav-1 cell invasion. In conclusion, Cav-1 expression leads to an increased proportion of HG-
CD147
relative to LG-
CD147
, increased production of MMP-11 and a higher invasive capability. Cav-1 is therefore proposed to act as both an oncogene and a tumor suppressor gene, and could represent a new potential target for gene therapy.
...
PMID:Caveolin-1 up-regulates CD147 glycosylation and the invasive capability of murine hepatocarcinoma cell lines. 1670 20
HAb18G/
CD147
, a membrane spanning molecule and highly expressed in
hepatocellular carcinoma
(
HCC
) cells, was shown to stimulate the production of matrix metalloproteinases (MMPs) in the interaction of tumor cells and fibroblasts. Studies on the
EMMPRIN
/
CD147
showed that
CD147
extracellular domain is involved in the induction of MMPs. To study the biological molecular function of HAb18G/
CD147
extracellular domain (HAb18G/
CD147
-ED) on production of MMPs following mediated tumor cell invasion, we isolated four novel monoclonal anibodies (MAbs)-1B3, 3B3, HAb18Gedomab1, and HAb18Gedomab2-against HAb18G/
CD147
-ED by immunization of BALB/c mice with purified HAb18G/
CD147
-ED fragments, which were efficiently expressed in Escherichia coli. Gelatin zymography and Boyden chamber assays were used to identify the production of MMPs in the co-cultured human fibroblast and
HCC
cells, and to quantify the migrated cells in the presence of the generated MAbs. The results showed that two MAbs (1B3 and 3B3) inhibited [corrected] the secretion of MMP-2 and [corrected] the
HCC
cell invasion, whereas the other two MAbs (HAb18Gedomab1 and HAb18Gedomab2) had reverse function [corrected] FCM additive assay showed that four MAbs recognized different epitopes of HAb18G/
CD147
-ED. Taken together, the results suggest that various regions of HAb18G/
CD147
-ED participated in the regulation of MMP secretion.
...
PMID:Regulation of matrix metalloproteinase production and tumor cell invasion by four monoclonal antibodies against different epitopes of HAb18G/CD147 extracellular domain. 1670 5
CD147
is a plasma membrane glycoprotein, enriched on the surface of many malignant tumor cells. As a result of heterogeneous N-glycosylation,
CD147
exists in both a highly glycosylated form, HG-
CD147
( approximately 40-60 kDa) and lowly glycosylated form, LG-
CD147
( approximately 32 kDa). This experiment investigated the possible role of
CD147
glycosylation in the HcaF, HcaP and Hepa1-6 mouse
hepatocarcinoma
cell lines, which have high, low and no metastatic potential in the lymph nodes. Western blot analysis showed that the ratio of HG-
CD147
/LG-
CD147
protein expression on HcaF and HcaP were much higher than that on Hepa1-6 cells. By treatment with tunicamycin (TM), an inhibitor of N-glycosylation, the expression level of HG-
CD147
decreased and the LG-
CD147
disappeared completely in HcaF cells. Meanwhile, Matrixmetallproteinase-11 (MMP-11) protein expression was down-regulated, and the adhesive capability of HcaF cells to endothelial cells in cryosection of mouse lymph nodes decreased. These results indicated that the glycosylation of
CD147
plays a crucial role. It is HG-
CD147
that may contribute more to tumor progress, invasion and metastasis into lymph node rather than LG-
CD147
. The results of this study are of biological and clinical importance.
...
PMID:Deglycosylation of CD147 down-regulates Matrix Metalloproteinase-11 expression and the adhesive capability of murine hepatocarcinoma cell HcaF in vitro. 1675 99
HAb18G/
CD147
has been identified as a factor that induces MMPs production. SiRNA targeted against HAb18G/
CD147
was transfected into FHCC-98 cells (a
HCC
cell line) to knockdown its expression. The results showed that downregulating HAb18G/
CD147
decreased ERK1/2, MMP-2 and FAK levels and inhibited cell motility and invasion, together with rearranged actin stress fiber formation, while had no effects on integrin alpha3beta1 expression. MEK1/2 inhibitor, U0126, inhibited MMP-2, FAK and actin expression in FHCC-98 cell line. The findings indicate that si-HAb18G inhibits gelatinase production, actin and FAK expression in FHCC-98 via an ERK1/2 signaling pathway.
...
PMID:siRNA targeted against HAb18G/CD147 inhibits MMP-2 secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. 1681 29
HAb18G/
CD147
is a highly glycosylated transmembrane protein belonging to the immunoglobulin superfamily. Our previous studies have demonstrated that overexpressing HAb18G/
CD147
enhances the metastatic potentials of human
hepatoma
cells. In the present study, to investigate the glycosylation characteristic of HAb18G/
CD147
in human
hepatoma
cells, HAb18G/
CD147
was first purified from human FHCC-98
hepatoma
cells by immunoaffinity chromatography, and then introduced into human fibroblasts culture system for matrix metalloproteinases induction. As a result, the elevated levels of matrix metalloproteinases secreted by fibroblasts were detected by gelatin zymography. The lysates of human
hepatoma
FHCC-98 cell revealed two major forms of HAb18G/
CD147
(43-66 and 35 kDa) by western blot assay. To elucidate whether the variation of molecule size were caused by different glycosylation, two different approaches were employed to accomplish this goal: deglycosylation with N-glycosylation inhibitor tunicamycin or endoglycosidases. A single deglycosylated core protein with molecular weight approximately 27 kDa was obtained from both methods. Furthermore, the results of endoglycosidases treatment also showed that two forms of HAb18G/
CD147
contain different types of oligosaccharide chains, thus sensitive to different endoglycosidase. In conclusion, the present study demonstrated that purified native HAb18G/
CD147
has the bioactivity of stimulating human fibroblasts to produce elevated levels of matrix metalloproteinases, and that the two different forms of HAb18G/
CD147
are derived from the single core protein but differ in their degree and types of glycosylation.
...
PMID:The glycosylation characteristic of hepatoma-associated antigen HAb18G/CD147 in human hepatoma cells. 1682 81
HAb18G/
CD147
, a new
hepatoma
-associated antigen cloned and screened from human
hepatocellular carcinoma
cDNA library, is closely correlated with metastasis process in human
hepatoma
cells. In the present study we aimed to identify the pivotal molecules of the HAb18G/
CD147
signal transduction pathway. The investigation showed that betaig-h3, a secretory extracellular matrix (ECM) protein, was upregulated in HAb18G/
CD147
-expressing human
hepatoma
T7721 cells and was downregulated by depressing HAb18G/
CD147
expression. The expression of betaig-h3, upregulated in human
hepatoma
cells, was positively relative to the expression of HAb18G/
CD147
in different human
hepatoma
cell lines. By overexpressing betaig-h3 in human SMMC-7721
hepatoma
cells, we discovered that betaig-h3 promoted cell adhesion, invasion, and matrix metalloproteinase (MMP) secretion potential. HAb18G/
CD147
-induced invasion and metastasis potential of human
hepatoma
cells can be attenuated by antibodies specific for betaig-h3, and no significant differences on inhibitory effects were observed among T7721 cells incubated with antibodies for betaig-h3 or HAb18G/
CD147
or both types together. Taken together, our study suggests that betaig-h3, regulated by the expression of HAb18G/
CD147
, is involved in the HAb18G/
CD147
signal transduction pathway and mediates the HAb18G/
CD147
-induced invasion and metastasis process of human
hepatoma
cells.
...
PMID:BetaIg-h3 is involved in the HAb18G/CD147-mediated metastasis process in human hepatoma cells. 1732 67
The aim of this study is to investigate whether the expression of
CD147
could be a prognostic factor for
hepatocellular carcinoma
. Tissue samples from 111
hepatocellular carcinoma
patients were immunohistochemically stained with anti-
CD147
, anti-matrix metalloproteinases-2 and anti-vascular endothelial growth factor antibodies. Tumor microvessel density was evaluated using CD34. The survival curves were estimated by Kaplan-Meier analysis and the prognostic significance of the marker was analyzed using the log-rank test. In addition, the identification of relevant prognostic factors was performed by multivariate Cox regression analysis.
CD147
was mainly expressed in cancerous lesions and its expression was positively correlated with metalloproteinases-2 (P<0.0001), vascular endothelial growth factor (P<0.0001) and microvessel density CD34 (P<0.0001). Furthermore,
CD147
was significantly associated with the presence of venous invasion (P=0.0013), tumor size (P<0.0001) and pTNM tumor stages (P=0.0001), as well as serum alpha-fetoprotein level (P<0.0001). Patients with positive expression of
CD147
had poorer tumor recurrence-free survival than those with negative expression of
CD147
(P<0.0001). Analyzed by a proportional hazard model, strong expression of
CD147
had the highest risk ratio of recurrence among these markers (P<0.0001). The findings suggest that
CD147
may be a significant independent predictor of poor survival in patients with
hepatocellular carcinoma
, and may be involved in tumor growth, invasion and angiogenesis in
hepatocellular carcinoma
.
...
PMID:Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. 1741 90
1
2
3
4
5
6
7
8
9
Next >>